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 Mixed background
◦ B.S. in Chemical Engineering (Caltech)
◦ PhD in Engineering/Psychology (UCLA)
 Research focus
◦ Technology Intelligence, Forecasting & Assessment
 Faculty – Georgia Tech (Professor Emeritus)
◦ Industrial & Systems Engineering, and
◦ Public Policy, and taught 10 years in
◦ Management  (Management of Technology – “MOT”)
 Small Business – Search Technology
◦ Decision aiding in complex environments since 1980
◦ Since 1994, develop & apply text mining software (VantagePoint) 
focusing on Science, Technology & Innovation (ST&I)
Nanotechnology-Enabled Drug Delivery (NEDD) – which 
A) nano components are helping deliver which B) drugs 
to treat which C) cancers?
◦ Are certain B) treatments (drugs, gene therapies) 
concentrated on C) certain cancers?
◦ Are A) certain nano components concentrated on C) certain 
cancers?
◦ Are A) certain nano components concentrated on 
facilitating delivery of B) certain treatments?
◦ Are there some shifts over time in treatment applications?
◦ Might there be some underexplored combinations of A) 
nano enabling components with B) drugs,  with C) cancer 
types?
Pointing toward further questions:
◦ How to facilitate discovery of such research opportunities?
◦ How might R&D policy/management better “connect” 
research in adjacent arenas?
But first, some background on our “tech mining” on NEDD
Douglas K. R. Robinson. TEQNODE Limited, Paris, France
Simple schematic of the “NEDD dream”
 Improve delivery of poorly soluble drugs
 Target delivery (get enough drug where you want it, and 
minimum drug where you don’t want it)
 Deliver large macromolecular drugs into cells (getting them 
through the natural barriers of cell walls)
 Co-deliver two or more drugs
 See where drugs go through incorporating tags
 Perform “theranostics” 
(if diagnostics can be added to the therapeutics)
Douglas K. R. Robinson. TEQNODE Limited, Paris, France
Nano Promises for Drug Delivery
Target-oriented Preparations, Shandong University
Different Kinds of Nanoparticles
 
  





























How do “nano” components work to treat diseases like cancer?
[deriving mainly from analyses of the NEDD patents]
No. Category Keywords
1 B (biological 
processes)
(bioavailab*or biodistrib* or biocompatib* or cytotox* or biodegradab*)
2 I (imaging) Image* or imaging
3 T (target) (Cancer or tumor* or tumour* or "RNA interference" or RNAi)
4 H (helpers) ("polyethylene glycol" or pegylate or PEG or molecule* or polymer* or polyethylenimine or PEI or polyspermine or 
polypropylenimine or "poly lactic-co-glycolic acid" or PLGA or cyclodextrin or dendrimer* or chitosan* or 
atelocollagen* or "hyaluronic acid" or polypeptid* or peptid* or lipid* or ligand* or or Micelle* or Liposom* or 
conjugat* or Viral* OR Virus* or nonvira* or non-vira*)
5 P(pharmaceutical) (1) (agent* or Drug* or pharmac* or formulation*)
(2) (siRNA or "short interfering RNA")
(3) microRNA
(4) DNA or gene
(5) (Dox or Doxorubicin*) 
(6) actives or adjuvant
6 D(delivery approach) (1) (deliver* or vehicle* or carrier* or vector*)
(2) (treat* or therap*)
(3)("control* releas*" or transduct* or transfect* or transport* or translocat*)
7 N(nano-delivery 
vehicle)
This category means GT nano Database or some approximation of its search terms; also consider viral or virus or 
dendrimer or colloid
NEDD Search Strategy
Zhou, X., Porter, A.L., Robinson, D.K.R., Zhang, Y., and Guo, Y. (to appear), Nano-enabled drug delivery: Recent trends, 
emerging issues, and future directions, in Islam, N. (ed.), Nanotechnology: Recent Trends, Emerging Issues and Future 
Directions, Nova Science Publishers, Hauppauge, NY.
Multi-part Boolean search to retrieve NEDD data
 ~60,000 Web of Science publication abstracts
 ~8,000 Derwent Innovation Index abstracts
 ~50,000 MEDLINE publication abstracts
Data & Analyses
NEDD research publication trends by Database Journal Coverage
Search Technology, 2014
 


























Developmental Pathways, Locating the 13 NEDD Topics of NEDD
[based mainly on the patent topical analyses]
Workshop with bio-medical & science policy 
colleagues at Georgia Tech (and 2d workshop at a 
Novel Drug Delivery Systems conference) – payoff 
will come from focusing on particular nano
components and/or targets
 One path: comparing NEDD for brain applications –
Alzheimer’s Disease and brain cancer
 Second path (today’s focus) – NEDD for cancer 
treatments
Feedback on the Empirical Research Profiling












Nanoparticle PEG and lactide 








Nanoparticle Topical Emergence in the Cancer Patent Dataset

NEDD + Cancers




#1 MeSH HEADING:exp: (Neoplasms OR Antineoplastic Agents) AND
(Drug carriers OR Micelles)
8715
#2 ((MeSH HEADING:exp: (Neoplasms OR Antineoplastic Agents) AND
Nanostructures) NOT #1) AND MeSH HEADING: (Drug Delivery
Systems OR RNA Small Interfering OR Gene Transfer Techniques OR
Delayed-Action Preparations OR RNA Interference OR Pharmaceutical
Vehicles OR Genetic Vectors OR Transfection OR Polyglycolic Acid)
1517
#3 ((((MeSH HEADING:exp: (Neoplasms OR Antineoplastic Agents) AND
Nanostructures) NOT #1) AND MeSH HEADING: (Doxorubicin OR




 National Library of Medicine colleagues reviewed the 
search strategy, suggesting some enhancements
◦ Focus on Medical Subject Headings (MeSH) is a good 
way to go
◦ Add some cancer terms
 MeSH “Qualifiers” offer good categorization (MeSH
assignment based on human indexer review of full articles)
 Current dataset of 10,354 MEDLINE abstract records
 Use VantagePoint desktop software 
(www.theVantagePoint.com) to separate ~3334 primary MeSH
terms and 73 Qualifiers in those 10,354 abstract records
 Focus on top 200 primary MeSH terms and 73 Qualifiers = 
matrix
 SPSS Hierarchical Clustering to consolidate those 200 MeSH
terms into 7 clusters
◦ Method – techniques, procedures, and programs
◦ Drug – drugs and formulas
◦ Component – nanoparticles and accompanied materials 
◦ Cancer – different cancer types
◦ Effect – effects of treatment
◦ Interface – receptors and metabolism
◦ Antibody – antibodies and antigens
Method Drug Component Cancer
Cancer 





















































































 3 key relationships to explore:
◦ Cancers (20) by Drugs (50)
◦ Cancers (20) by Nano components (62)
◦ Drugs (50) by Nano components (62)
 But really more than 2-D – additional dimensions to 
explore:
◦ Density [intensity of research publication]
◦ What? + Who? Where? When?
◦ Other 4 of the 7 MeSH Qualifier clusters:  methods, 
effects, interfaces, antibodies

a) Column (agent) proportion – of 580 Doxorubicin (DOX) hits (as Primary MeSH for these 
20 cancers), what proportion are directed at each cancer type?
b) Row (cancer) Proportion – what proportion of these are bone neoplasm studies? 
(etc.)
Divide a/b to look at relative research concentrations (cells)
Agent profiling: DOX -- Used for all 20; sarcoma & bone neoplasm most:
Paclitaxel used for all but one (lymphoma) – why not?
Cancer profiling: Leukemia – 5 drugs overwhelmingly used to treat this 
– see earlier matrix 
Agent for Cancer;  Explore the zeroes with biomedical scientists
Examine groups of agents or cancers: genetic treatments [RNAi & 
DNA] – notably widely used.
Crosswalk: explore why RNAi is not showing for peritoneal neoplasms, but 
DNA is?  Also, DNA is prominent for uterine cervical, why less so RNAi?
Look at narrowly targeted agents; might they hold potential for others?
3879 Col Sum 704 580 248 224 89 319 7
# Records 2697 1476 713 430 212 864 45
# Records CANCERS \ AGENTS Antineopla  Doxorubici Paclitaxel RNA, Sma  DNA Antibiotics, Etoposide
627 Breast Neoplasms 0.79 1.51 1.37 0.83 0.42 1.34 0.88
490 Brain and Nerve Neoplasms 1.02 0.78 1.12 0.85 1.16 0.77 2.26
397 Liver Neoplasms 0.96 1.43 0.59 1.00 1.76 1.72 0.00
376 Lung Neoplasms 1.10 0.80 1.33 1.70 1.16 0.81 2.95
356 Skin Neoplasms 1.05 0.83 0.53 0.78 1.59 0.75 0.00
269 Colorectal Neoplasms 1.09 0.72 0.70 0.52 0.32 0.54 0.00
237 Ovarian Neoplasms 1.05 1.50 2.11 1.46 0.55 1.74 0.00
208 Prostatic Neoplasms 0.90 0.71 0.38 2.41 1.26 0.47 0.00
133 Adenocarcinoma 0.91 0.75 0.82 0.65 1.31 0.82 0.00
131 Leukemia 0.72 0.36 0.12 0.13 0.33 1.58 0.00
122 Pancreatic Neoplasms 1.45 0.22 0.77 0.71 2.14 0.20 0.00
114 Carcinoma, Squamous Cell 0.77 0.47 0.69 0.61 0.76 0.43 0.00
79 Stomach Neoplasms 0.91 0.25 1.78 1.10 0.55 0.62 0.00
67 Bone Neoplasms 1.40 1.90 0.47 1.29 0.65 0.73 0.00
59 Head and Neck Neoplasms 1.21 1.13 0.27 0.88 0.00 1.03 0.00
53 Urinary Bladder Neoplasms 1.04 0.76 2.95 1.63 0.00 1.38 0.00
51 Peritoneal Neoplasms 1.94 0.92 1.23 0.00 0.85 0.72 0.00
38 Uterine Cervical Neoplasms 0.87 0.70 1.65 1.37 3.44 0.64 0.00
37 Lymphoma 0.74 0.90 0.00 0.47 0.00 0.66 29.95





+ other drugs (multi-
drug delivery?)
Address 4958 of the 10,354 articles; spotlighted a row (one agent) –




Only 10 also entail DNA?
Spotlight on skin neoplasms with its most prominent nano delivery 
component, liposomes (55 articles)





 Agent by Agent – how much “combo” treatment?
[multiple drug delivery via NEDD]
 Nano component by Nano component – in conjunction?
 Explore the other 4 clusters – methods, effects, etc.
 Pursue “who, what, where, when” elements on subsets of interest –
e.g., leading journals, leading researchers, etc.  
 Text mining software:
http://www.theVantagePoint.com
 Global Tech Mining Conference, in conjunction with the 
S&T Indicators Conference, 2-5 Sep., 2014, Leiden, The 
Netherlands 
www.gtmconference.org
 Future-oriented Technology Analysis Conference, 27-28 
November, 2014, Brussels, Belgium
//forera.jrc.ec.europa.eu/
Resources
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Can we “discover” opportunities via such tech mining?
 Research gap analyses – could nano component X 
also facilitate delivery of treatment Y, for disease Z?
 Could such R&D profiling/parsing help in your 
studies?
 Could we boost research proposals by 
incorporating such nano R&D profiling to explore 
“connections”? 
 How do you learn about “one step removed” 
research findings, methods, applications, etc.?
 Could you help us interpret NEDD relationships?
Discussion??
Nano grafted on current pharma
TDS (illustrated for cancer]
Co-development of NEDD with 
drug
Multi-functional 
nanotherapies

